rigosertib sodium

DRUG4 trials

Sponsors

Traws Pharma, Inc., Thomas Jefferson University

Conditions

Advanced CancerCancerChronic Myelomonocytic LeukemiaCytopeniaMyelodysplastic SyndromesNeoplasmsRecessive Dystrophic Epidermolysis BullosaRefractory Anemia With Excess Blasts

Early Phase 1

Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC

CompletedNCT04177498

Thomas Jefferson UniversityRecessive Dystrophic Epidermolysis Bullosa

Start: 2021-08-24End: 2025-05-05Updated: 2025-08-01

Phase 1

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

CompletedNCT01538563

Traws Pharma, Inc.Advanced Cancer, Cancer, Neoplasms +1

Start: 2006-06-30End: 2011-11-30Updated: 2017-06-23

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

CompletedNCT01538537

Traws Pharma, Inc.Advanced Cancer, Cancer, Neoplasms +1

Start: 2006-08-31End: 2012-01-31Updated: 2017-06-23

Phase 3

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

CompletedNCT01928537

Traws Pharma, Inc.Chronic Myelomonocytic Leukemia, Cytopenia, Myelodysplastic Syndromes +1

Start: 2013-08-31End: 2017-06-29Updated: 2020-06-30

Related Papers

Abstract 2033: Rigosertib promotes anti-tumor activity of cancer cells via CETSA revealed novel targets and activates NLRP3-dependent inflammatory responses

Cancer Research2024-03-22

A pilot, open study to assess efficacy and safety of ON-01910 (rigosertib) in patients with recessive dystrophic epidermolysis bullosa associated locally advanced/metastatic squamous cell carcinoma.

Journal of Clinical Oncology2023-06-01